• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Mirabegron as a new class of oral drug for overactive bladder syndrome: many positive perspectives, some concerns.

作者信息

Novara Giacomo, Cornu Jean-Nicolas

出版信息

Eur Urol. 2013 Feb;63(2):306-8. doi: 10.1016/j.eururo.2012.11.024. Epub 2012 Nov 16.

DOI:10.1016/j.eururo.2012.11.024
PMID:23201469
Abstract
摘要

相似文献

1
Mirabegron as a new class of oral drug for overactive bladder syndrome: many positive perspectives, some concerns.米拉贝隆作为治疗膀胱过度活动症的新型口服药物：诸多积极方面，也存在一些担忧。
Eur Urol. 2013 Feb;63(2):306-8. doi: 10.1016/j.eururo.2012.11.024. Epub 2012 Nov 16.
2
Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.米拉贝隆（一种β（3）-肾上腺素能受体激动剂）治疗膀胱过度活动症的疗效和耐受性：一项随机、欧洲-澳大利亚 3 期试验的结果。
Eur Urol. 2013 Feb;63(2):283-95. doi: 10.1016/j.eururo.2012.10.016. Epub 2012 Nov 6.
3
Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder.米拉贝隆治疗膀胱过度活动症的随机、双盲、阳性药物对照 3 期临床试验：12 个月安全性和疗效评估
Eur Urol. 2013 Feb;63(2):296-305. doi: 10.1016/j.eururo.2012.10.048. Epub 2012 Nov 6.
4
Flexible dose fesoterodine in the treatment of overactive bladder (OAB).
BJU Int. 2013 Aug;112(3):281-2. doi: 10.1111/bju.12319.
5
Understanding the effects on HR-QoL of treatment for overactive bladder: a detailed analysis of EQ-5D clinical trial data for mirabegron.了解治疗过度活跃膀胱对 HR-QoL 的影响：米拉贝隆 EQ-5D 临床试验数据的详细分析。
J Med Econ. 2013 Jul;16(7):866-76. doi: 10.3111/13696998.2013.802240. Epub 2013 May 20.
6
The role of mirabegron in overactive bladder: a systematic review and meta-analysis.米拉贝隆在膀胱过度活动症中的作用：一项系统评价和荟萃分析。
Urol Int. 2014;93(3):326-37. doi: 10.1159/000361079. Epub 2014 Aug 7.
7
Treatment of men with lower urinary tract symptoms and overactive bladder.
JAMA. 2007 Mar 21;297(11):1192; author reply 1193. doi: 10.1001/jama.297.11.1192-a.
8
Overactive bladder disease: the urge for better therapies.膀胱过度活动症：对更好疗法的需求。
J Manag Care Pharm. 2008 May;14(4):381-6. doi: 10.18553/jmcp.2008.14.4.381.
9
Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year.米拉贝隆50毫克每日一次用于治疗膀胱过度活动症症状：12周及1年的疗效和耐受性概述
Int J Urol. 2014 Oct;21(10):960-7. doi: 10.1111/iju.12568. Epub 2014 Aug 4.
10
Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
J Urol. 2006 Nov;176(5):2311-2; author reply 2312-3. doi: 10.1016/j.juro.2006.06.053.

引用本文的文献

1
Efficacy and safety of mirabegron in the treatment of overactive bladder syndrome after radical prostatectomy: a prospective randomized controlled study.米拉贝隆治疗前列腺癌根治术后膀胱过度活动症综合征的疗效和安全性：一项前瞻性随机对照研究。
Front Oncol. 2023 May 2;13:1188619. doi: 10.3389/fonc.2023.1188619. eCollection 2023.
2
Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis.米拉贝隆与抗胆碱能疗法在膀胱过度活动症患者中的依从性和持续性：一项真实世界索赔数据分析
Int J Clin Pract. 2017 Mar;71(3-4). doi: 10.1111/ijcp.12824.
3
Postmenopausal overactive bladder.
绝经后膀胱过度活动症
Prz Menopauzalny. 2014 Dec;13(6):313-29. doi: 10.5114/pm.2014.47984. Epub 2014 Dec 30.